Symptom  ||| S:0 E:8 ||| JJ
control  ||| S:8 E:16 ||| NN
in  ||| S:16 E:19 ||| IN
patients  ||| S:19 E:28 ||| NNS
with  ||| S:28 E:33 ||| IN
recurrent  ||| S:33 E:43 ||| JJ
ovarian  ||| S:43 E:51 ||| JJ
cancer ||| S:51 E:57 ||| NN
:  ||| S:57 E:59 ||| :
measuring  ||| S:59 E:69 ||| VBG
the  ||| S:69 E:73 ||| DT
benefit  ||| S:73 E:81 ||| NN
of  ||| S:81 E:84 ||| IN
palliative  ||| S:84 E:95 ||| JJ
chemotherapy  ||| S:95 E:108 ||| NN
in  ||| S:108 E:111 ||| IN
women  ||| S:111 E:117 ||| NNS
with  ||| S:117 E:122 ||| IN
platinum  ||| S:122 E:131 ||| FW
refractory ||| S:131 E:141 ||| FW
/ ||| S:141 E:142 ||| FW
resistant  ||| S:142 E:152 ||| FW
ovarian  ||| S:152 E:160 ||| FW
cancer  ||| S:160 E:167 ||| NN
Most  ||| S:167 E:172 ||| JJS
women  ||| S:172 E:178 ||| NNS
with  ||| S:178 E:183 ||| IN
advanced  ||| S:183 E:192 ||| JJ
ovarian  ||| S:192 E:200 ||| JJ
cancer  ||| S:200 E:207 ||| NN
will  ||| S:207 E:212 ||| MD
relapse  ||| S:212 E:220 ||| VB
and  ||| S:220 E:224 ||| CC
subsequently  ||| S:224 E:237 ||| RB
develop  ||| S:237 E:245 ||| VB
platinum-resistant ||| S:245 E:263 ||| JJ
/ ||| S:263 E:264 ||| CD
refractory  ||| S:264 E:275 ||| JJ
ovarian  ||| S:275 E:283 ||| JJ
cancer ||| S:283 E:289 ||| NN
.  ||| S:289 E:291 ||| .
The  ||| S:291 E:295 ||| DT
benefit  ||| S:295 E:303 ||| NN
of  ||| S:303 E:306 ||| IN
treatment  ||| S:306 E:316 ||| NN
is  ||| S:316 E:319 ||| VBZ
currently  ||| S:319 E:329 ||| RB
based  ||| S:329 E:335 ||| VBN
on  ||| S:335 E:338 ||| IN
objective  ||| S:338 E:348 ||| JJ
response  ||| S:348 E:357 ||| NN
rates ||| S:357 E:362 ||| NNS
,  ||| S:362 E:364 ||| ,
which  ||| S:364 E:370 ||| WDT
are  ||| S:370 E:374 ||| VBP
a  ||| S:374 E:376 ||| DT
crude  ||| S:376 E:382 ||| JJ
measure  ||| S:382 E:390 ||| NN
of  ||| S:390 E:393 ||| IN
benefit ||| S:393 E:400 ||| NN
.  ||| S:400 E:402 ||| .
It  ||| S:402 E:405 ||| PRP
would  ||| S:405 E:411 ||| MD
be  ||| S:411 E:414 ||| VB
clinically  ||| S:414 E:425 ||| RB
meaningful  ||| S:425 E:436 ||| JJ
if  ||| S:436 E:439 ||| IN
we  ||| S:439 E:442 ||| PRP
were  ||| S:442 E:447 ||| VBD
better  ||| S:447 E:454 ||| RBR
able  ||| S:454 E:459 ||| JJ
to  ||| S:459 E:462 ||| TO
measure  ||| S:462 E:470 ||| VB
the  ||| S:470 E:474 ||| DT
benefit  ||| S:474 E:482 ||| NN
of  ||| S:482 E:485 ||| IN
palliative  ||| S:485 E:496 ||| JJ
therapy  ||| S:496 E:504 ||| NN
and ||| S:504 E:507 ||| CC
,  ||| S:507 E:509 ||| ,
in  ||| S:509 E:512 ||| IN
particular ||| S:512 E:522 ||| JJ
,  ||| S:522 E:524 ||| ,
ascertain  ||| S:524 E:534 ||| VBG
whether  ||| S:534 E:542 ||| IN
cancer-related  ||| S:542 E:557 ||| JJ
symptoms  ||| S:557 E:566 ||| NNS
improve  ||| S:566 E:574 ||| VBP
with  ||| S:574 E:579 ||| IN
treatment  ||| S:579 E:589 ||| NN
and  ||| S:589 E:593 ||| CC
how  ||| S:593 E:597 ||| WRB
this  ||| S:597 E:602 ||| DT
impacts  ||| S:602 E:610 ||| NN
on  ||| S:610 E:613 ||| IN
quality  ||| S:613 E:621 ||| NN
of  ||| S:621 E:624 ||| IN
life ||| S:624 E:628 ||| NN
.  ||| S:628 E:630 ||| .
This  ||| S:630 E:635 ||| DT
paper  ||| S:635 E:641 ||| NN
reviews  ||| S:641 E:649 ||| VBZ
the  ||| S:649 E:653 ||| DT
management  ||| S:653 E:664 ||| NN
of  ||| S:664 E:667 ||| IN
patients  ||| S:667 E:676 ||| NNS
with  ||| S:676 E:681 ||| IN
platinum-resistant ||| S:681 E:699 ||| JJ
/ ||| S:699 E:700 ||| CD
refractory  ||| S:700 E:711 ||| JJ
ovarian  ||| S:711 E:719 ||| JJ
cancer  ||| S:719 E:726 ||| NN
and  ||| S:726 E:730 ||| CC
highlights  ||| S:730 E:741 ||| VBZ
the  ||| S:741 E:745 ||| DT
gaps  ||| S:745 E:750 ||| NN
in  ||| S:750 E:753 ||| IN
our  ||| S:753 E:757 ||| PRP$
knowledge  ||| S:757 E:767 ||| NN
and  ||| S:767 E:771 ||| CC
shortcomings  ||| S:771 E:784 ||| NNS
with  ||| S:784 E:789 ||| IN
the  ||| S:789 E:793 ||| DT
current  ||| S:793 E:801 ||| JJ
approaches  ||| S:801 E:812 ||| NNS
to  ||| S:812 E:815 ||| TO
measure  ||| S:815 E:823 ||| VB
the  ||| S:823 E:827 ||| DT
benefit  ||| S:827 E:835 ||| NN
of  ||| S:835 E:838 ||| IN
treatment ||| S:838 E:847 ||| NN
.  ||| S:847 E:849 ||| .
The  ||| S:849 E:853 ||| DT
ultimate  ||| S:853 E:862 ||| JJ
objective  ||| S:862 E:872 ||| NN
is  ||| S:872 E:875 ||| VBZ
to  ||| S:875 E:878 ||| TO
describe  ||| S:878 E:887 ||| VB
and  ||| S:887 E:891 ||| CC
encourage  ||| S:891 E:901 ||| VB
recruitment  ||| S:901 E:913 ||| VBN
to  ||| S:913 E:916 ||| TO
the  ||| S:916 E:920 ||| DT
Gynecologic  ||| S:920 E:932 ||| NNP
Cancer  ||| S:932 E:939 ||| NNP
Intergroup  ||| S:939 E:950 ||| NNP
study  ||| S:950 E:956 ||| NN
that  ||| S:956 E:961 ||| WDT
has  ||| S:961 E:965 ||| VBZ
recently  ||| S:965 E:974 ||| RB
opened ||| S:974 E:980 ||| VBN
.  ||| S:980 E:982 ||| .
This  ||| S:982 E:987 ||| DT
study  ||| S:987 E:993 ||| NN
will  ||| S:993 E:998 ||| MD
recruit  ||| S:998 E:1006 ||| VB
a  ||| S:1006 E:1008 ||| DT
large  ||| S:1008 E:1014 ||| JJ
number  ||| S:1014 E:1021 ||| NN
of  ||| S:1021 E:1024 ||| IN
patients  ||| S:1024 E:1033 ||| NNS
from  ||| S:1033 E:1038 ||| IN
around  ||| S:1038 E:1045 ||| IN
the  ||| S:1045 E:1049 ||| DT
world  ||| S:1049 E:1055 ||| NN
in  ||| S:1055 E:1058 ||| IN
an  ||| S:1058 E:1061 ||| DT
effort  ||| S:1061 E:1068 ||| NN
to  ||| S:1068 E:1071 ||| TO
develop  ||| S:1071 E:1079 ||| VB
more  ||| S:1079 E:1084 ||| RBR
robust  ||| S:1084 E:1091 ||| JJ
instruments  ||| S:1091 E:1103 ||| NNS
to  ||| S:1103 E:1106 ||| TO
measure  ||| S:1106 E:1114 ||| VB
the  ||| S:1114 E:1118 ||| DT
benefit  ||| S:1118 E:1126 ||| NN
of  ||| S:1126 E:1129 ||| IN
chemotherapy  ||| S:1129 E:1142 ||| NN
and  ||| S:1142 E:1146 ||| CC
to  ||| S:1146 E:1149 ||| TO
understand  ||| S:1149 E:1160 ||| VB
the  ||| S:1160 E:1164 ||| DT
impact  ||| S:1164 E:1171 ||| NN
of  ||| S:1171 E:1174 ||| IN
chemotherapy  ||| S:1174 E:1187 ||| NN
on  ||| S:1187 E:1190 ||| IN
symptom  ||| S:1190 E:1198 ||| JJ
control  ||| S:1198 E:1206 ||| NN
and  ||| S:1206 E:1210 ||| CC
quality  ||| S:1210 E:1218 ||| NN
of  ||| S:1218 E:1221 ||| IN
life ||| S:1221 E:1225 ||| NN
.  ||| S:1225 E:1227 ||| .
In  ||| S:1227 E:1230 ||| IN
addition ||| S:1230 E:1238 ||| NN
,  ||| S:1238 E:1240 ||| ,
this  ||| S:1240 E:1245 ||| DT
study  ||| S:1245 E:1251 ||| NN
will  ||| S:1251 E:1256 ||| MD
give  ||| S:1256 E:1261 ||| VB
us  ||| S:1261 E:1264 ||| PRP
an  ||| S:1264 E:1267 ||| DT
insight  ||| S:1267 E:1275 ||| NN
into  ||| S:1275 E:1280 ||| IN
how  ||| S:1280 E:1284 ||| WRB
all  ||| S:1284 E:1288 ||| DT
patients  ||| S:1288 E:1297 ||| NNS
are  ||| S:1297 E:1301 ||| VBP
managed  ||| S:1301 E:1309 ||| VBN
rather  ||| S:1309 E:1316 ||| RB
than  ||| S:1316 E:1321 ||| IN
a  ||| S:1321 E:1323 ||| DT
select  ||| S:1323 E:1330 ||| JJ
minority  ||| S:1330 E:1339 ||| NN
who  ||| S:1339 E:1343 ||| WP
are  ||| S:1343 E:1347 ||| VBP
treated  ||| S:1347 E:1355 ||| VBN
in  ||| S:1355 E:1358 ||| IN
clinical  ||| S:1358 E:1367 ||| JJ
trials ||| S:1367 E:1373 ||| NNS
.  ||| S:1373 E:1375 ||| .
